Crinetics Pharmaceuticals (CRNX) Scheduled to Post Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 52.93%. During the same period in the prior year, the business earned ($0.84) earnings per share. The company's revenue was down 100.0% compared to the same quarter last year. On average, analysts expect Crinetics Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 0.9 %

Crinetics Pharmaceuticals stock traded up $0.42 during midday trading on Friday, reaching $47.20. The stock had a trading volume of 679,390 shares, compared to its average volume of 764,705. Crinetics Pharmaceuticals has a 12 month low of $15.76 and a 12 month high of $49.58. The company has a market capitalization of $3.72 billion, a P/E ratio of -12.86 and a beta of 0.63. The company has a fifty day moving average price of $43.62 and a two-hundred day moving average price of $37.16.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CRNX shares. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Crinetics Pharmaceuticals in a research report on Tuesday, March 19th. JMP Securities reissued a "market outperform" rating and set a $80.00 price objective on shares of Crinetics Pharmaceuticals in a report on Thursday, March 28th. Morgan Stanley started coverage on Crinetics Pharmaceuticals in a report on Tuesday, January 16th. They set an "overweight" rating and a $50.00 price objective for the company. Cantor Fitzgerald boosted their price objective on Crinetics Pharmaceuticals from $50.00 to $65.00 and gave the stock an "overweight" rating in a report on Monday, March 4th. Finally, Robert W. Baird boosted their price objective on Crinetics Pharmaceuticals from $45.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $54.00.

Insider Activity

In other news, CEO Richard Scott Struthers sold 40,951 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $49.17, for a total value of $2,013,560.67. Following the completion of the transaction, the chief executive officer now directly owns 237,835 shares of the company's stock, valued at $11,694,346.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Dana Pizzuti sold 15,089 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.06, for a total value of $664,821.34. Following the transaction, the insider now owns 27,786 shares in the company, valued at $1,224,251.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Richard Scott Struthers sold 40,951 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $49.17, for a total value of $2,013,560.67. Following the completion of the transaction, the chief executive officer now owns 237,835 shares in the company, valued at approximately $11,694,346.95. The disclosure for this sale can be found here. Insiders sold a total of 187,216 shares of company stock valued at $8,509,397 over the last three months. Corporate insiders own 7.00% of the company's stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.